| Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab A Gupta, Y Gonzalez-Rojas, E Juarez, M Crespo Casal, J Moya, DR Falci, ... New England Journal of Medicine 385 (21), 1941-1950, 2021 | 1129 | 2021 |
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 423 | 2019 |
| Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 … JM Llibre, CC Hung, C Brinson, F Castelli, PM Girard, LP Kahl, EA Blair, ... The Lancet 391 (10123), 839-849, 2018 | 413 | 2018 |
| Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised … KH Mayer, JM Molina, MA Thompson, PL Anderson, KC Mounzer, ... The Lancet 396 (10246), 239-254, 2020 | 379 | 2020 |
| Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection C Orkin, K Arasteh, M Górgolas Hernández-Mora, V Pokrovsky, ... New England Journal of Medicine 382 (12), 1124-1135, 2020 | 374 | 2020 |
| Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial A Gupta, Y Gonzalez-Rojas, E Juarez, MC Casal, J Moya, DR Falci, ... Jama 327 (13), 1236-1246, 2022 | 263 | 2022 |
| Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 … DA Margolis, CC Brinson, GHR Smith, J de Vente, DP Hagins, JJ Eron, ... The Lancet infectious diseases 15 (10), 1145-1155, 2015 | 246 | 2015 |
| Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 … JE Gallant, ES Daar, F Raffi, C Brinson, P Ruane, E DeJesus, M Johnson, ... The lancet HIV 3 (4), e158-e165, 2016 | 212 | 2016 |
| Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 … JM Molina, D Ward, I Brar, A Mills, HJ Stellbrink, L López-Cortés, P Ruane, ... The Lancet HIV 5 (7), e357-e365, 2018 | 176 | 2018 |
| Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a … DA Wohl, Y Yazdanpanah, A Baumgarten, A Clarke, MA Thompson, ... The lancet HIV 6 (6), e355-e363, 2019 | 158 | 2019 |
| Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and … D Wohl, S Oka, N Clumeck, A Clarke, C Brinson, J Stephens, K Tashima, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 72 (1), 58-64, 2016 | 147 | 2016 |
| Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, phase IIIb study B Trottier, JE Lake, K Logue, C Brinson, L Santiago, C Brennan, JA Koteff, ... Antiviral therapy 22 (4), 295-305, 2017 | 145 | 2017 |
| Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study C Orkin, S Oka, P Philibert, C Brinson, A Bassa, D Gusev, O Degen, ... The Lancet HIV 8 (4), e185-e196, 2021 | 130 | 2021 |
| Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir+ rilpivirine (LATTE-2) in the United States and Spain D Kerrigan, A Mantsios, M Gorgolas, ML Montes, F Pulido, C Brinson, ... PloS one 13 (1), e0190487, 2018 | 130 | 2018 |
| Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat … C Orkin, JM Molina, E Negredo, JR Arribas, J Gathe, JJ Eron, ... The Lancet HIV 5 (1), e23-e34, 2018 | 127 | 2018 |
| Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate–based single-tablet regimens AM Mills, C Cohen, E DeJesus, C Brinson, S Williams, KL Yale, ... HIV Clinical Trials 14 (5), 216-223, 2013 | 113 | 2013 |
| Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial PE Sax, E DeJesus, G Crofoot, D Ward, P Benson, R Dretler, A Mills, ... The lancet HIV 4 (4), e154-e160, 2017 | 105 | 2017 |
| Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results … C Orkin, E DeJesus, PE Sax, JR Arribas, SK Gupta, C Martorell, ... The Lancet HIV 7 (6), e389-e400, 2020 | 95 | 2020 |
| Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial EA Bohula, BM Scirica, SE Inzucchi, DK McGuire, AC Keech, SR Smith, ... The Lancet 392 (10161), 2269-2279, 2018 | 93 | 2018 |
| Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1–infected, treatment-experienced, CCR5 antagonist–naive subjects J Lalezari, J Gathe, C Brinson, M Thompson, C Cohen, E Dejesus, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 57 (2), 118-125, 2011 | 88 | 2011 |
